2026 Cardiometabolic and Weight-Loss Watchlist: Trials That Could Mint the Next Trillion-Dollar Giant

The 2026 biotech landscape is no longer defined by post-pandemic recovery, but by a high-velocity race toward the first $150 billion therapeutic market. Following a massive 33.4% surge in the Nasdaq Biotechnology Index (NBI) in 2025, the sector has transitioned from survival to a “risk-on” growth phase. At the heart of this rally is the obesity and metabolic revolution; with Eli Lilly and Novo Nordisk alone generating over $75 billion in combined annual GLP-1 revenue, investors are closely monitoring the next wave of clinical readouts. As we enter the first half of 2026, the industry is bracing for pivotal trial data that could determine which players will capture a market projected to hit $150 billion by 2035.

The Multi-Hormone Frontier in Obesity

The weight loss market remains the primary engine for biotech valuations. In 2026, the battle for supremacy centers on moving beyond single-hormone treatments to more potent, “triple-acting” and combination therapies.

Eli Lilly: Retatrutide (TRIUMPH-1, -2, -3)

Eli Lilly currently leads the obesity market, but its next-generation “triple G” agonist, retatrutide, aims to raise the bar. Unlike current dual-acting treatments, retatrutide targets GLP-1, GIP, and glucagon.

• The Trials: TRIUMPH-1 (NCT05929066) focuses on general obesity; TRIUMPH-2 (NCT05929079) targets patients with type 2 diabetes; and TRIUMPH-3 (NCT05929092) evaluates those with cardiovascular disease.
• The Stakes: Previous data showed weight loss nearing 29% over a year. Success in the TRIUMPH series would likely secure Lilly’s dominance before Novo Nordisk can bring a similar triple-acting therapy to market.

The Novo Nordisk Counter-Offensive: Lilly’s chief rival, Novo Nordisk, is not standing still. Having just launched the first-ever oral GLP-1 for weight loss (the Wegovy pill) in early January 2026, Novo is now pivoting to its own next-generation multi-hormone therapies. The company is preparing to move amycretin—a dual GLP-1 and amylin agonist—into a massive Phase 3 program this year following mid-stage results that showed weight loss of 22% over 36 weeks. Novo is also advancing CagriSema of the REDEFINE-2 trial (NCT05394519), with a regulatory filing expected this quarter, aiming to prove its combination therapy can match or exceed the potency of Lilly’s best-selling tirzepatide.

Targeting Lipoprotein(a): The New Frontier in Cardiology

While the weight loss market captures headlines, a separate race is occurring in “residual” cardiovascular risk. Focus has shifted to Lipoprotein(a) [Lp(a)], a genetically determined heart risk factor that cannot be lowered by traditional statins.

Novartis: Pelacarsen (Lp(a)HORIZON)

Novartis is positioned to be the first-mover in this multi-billion-dollar market.

• The Trial: Lp(a)HORIZON (NCT04023552) is an event-driven study involving over 8,000 participants.
• The Stakes: This trial will prove whether an RNA-based approach can reduce actual heart attacks and strokes. Success would validate a multi-billion-dollar market and set a precedent for rivals Amgen and Eli Lilly.

The Fast-Following Field: While Novartis aims for a first-mover advantage, the competition is closing in with potentially more potent or convenient delivery systems. Amgen is currently advancing olpasiran in its own massive Phase 3 study, OCEAN(a) (NCT05581303). Recent data from its Phase 2 “DOSE” trial showed that olpasiran reduced Lp(a) levels by more than 95%, with effects lasting nearly a year after the last injection. Amgen is now testing the drug’s ability to prevent heart disease deaths and strokes in over 7,200 patients, with a data readout expected by the end of 2026.

Meanwhile, Eli Lilly is pursuing a two-pronged strategy to capture the market. Its lead injectable candidate, lepodisiran, entered the Phase 3 ACCLAIM-Lp(a) trial (NCT06292013) after mid-stage results demonstrated a staggering 94% reduction in Lp(a) that remained durable for nearly six months from a single dose. Perhaps even more disruptive is Lilly’s second asset, muvalaplin. Currently in Phase 3 “MOVE-Lp(a)” (NCT07157774) testing, muvalaplin is a once-daily pill—a potential “game-changer” for patients who prefer oral medication over the subcutaneous injections required by Novartis and Amgen.

Precision Cardiology: Targeting Heart Muscle directly

While the broader market focuses on lipids and metabolism, the field of cardiac myosin inhibitors is revolutionizing the treatment of hypertrophic cardiomyopathy (HCM).

Cytokinetics: Aficamten (ACACIA-HCM)

Following the recent approval of Myqorzo, Cytokinetics is looking to expand into “non-obstructive” HCM, a segment where Bristol Myers Squibb’s Camzyos recently failed.

• The Trial: ACACIA-HCM (NCT05116176) evaluates the drug’s impact on oxygen consumption and heart health.
• The Stakes: Approximately one-third of HCM patients have the non-obstructive form, which currently has no approved targeted therapies. If successful, aficamten could become the “best and only” drug for the entire HCM spectrum, potentially doubling its revenue projections and cementing its status as a multi-billion-dollar blockbuster, and potentially displacing Camzyos as the preferred cardiac myosin inhibitor.

The Battle of the Myosin Inhibitors: The competition between Cytokinetics and Bristol Myers Squibb (BMS) has become one of the most-watched rivalries in cardiology. While BMS had a multi-year head start with Camzyos, its failure in the Phase 3 nHCM trial (announced in April 2025) has left the door wide open. Investigators suggested that nHCM is a “unique disease” compared to the obstructive form, leading to skepticism that any myosin inhibitor could work.

However, Cytokinetics is banking on several key differentiators. Aficamten features a significantly shorter half-life than Camzyos. This allows for faster dose titration during treatment. Patients also experience more rapid heart function recovery if therapy pauses. Furthermore, aficamten avoids complex drug-drug interaction monitoring. It lacks the specific embryo-fetal toxicity warnings found on the Camzyos label. Preliminary data from the FOREST-HCM extension study (NCT04848506) shows sustained symptom improvement. Management expects these signals to translate into a Phase 3 victory. Topline results will arrive in the second quarter of 2026.

The 2026 Inflection Point

The 2026 clinical readouts represent more than just data points; they signal a definitive transition for the entire cardiometabolic investment landscape. With the anti-obesity market alone on a trajectory toward $150 billion by 2035, these results will establish permanent market dominance rather than simply validating individual drugs.

This high-stakes environment arrives just as looming “patent cliffs” force large-cap pharmaceutical giants to act with newfound aggression. These titans must replace billions in lost revenue before 2030, making successful Phase 3 assets the ultimate prize. Consequently, positive data will likely trigger immediate strategic acquisitions as buyers prioritize de-risked innovation with near-term revenue potential. In this climate, the coming months will determine which players fall behind and which will be minted as the next generation of healthcare giants.

Author

Bernice Lottering